Financials and Corporate
Innate Pharma raises 50 million euros in a capital increase subscribed by specialist institutional investors
This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only. Innate Pharma S.A....
Innate pharma launches a capital increase to raise up to 15% of current capital
This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only. Innate pharma launches...
Innate Pharma announces revenue for the first three months of 2014 and updates on its cash Position
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of...
Highlights from Innate Pharma's R&D update
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D...
Number of shares and voting rights of Innate Pharma as at April 4, 2014
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...
Outcome of Annual General Meeting of March 27, 2014
Approval of issuance of 600,000 shares reserved to Novo Nordisk A/S as contemplated by the agreement on NKG2A checkpoint inhibitor acquisition by Innate Pharma Innate Pharma (Euronext Paris...
Number of shares and voting rights of Innate Pharma as at March 24, 2014
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...
R&D Update on April 10, 2014 in New York
Innate Pharma will update investors and analysts on its pipeline and strategy The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II...
Number of shares and voting rights of Innate Pharma as at March 7, 2014
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...